CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Reprogramming compromised immune cells to fight cancer
Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...
chromatographyonline1d
Advancing Gene Therapy: Enzyme Selection For Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), ...
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...
The EMBO Journal2d
A CRISPR-Cas9 screen reveals genetic determinants of the cellular response to decitabine
A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...
Impacts2d
Unveiling the Power of CRISPR Screening in Modern Genomics
CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...
Hosted on MSN5d
New CRISPR Tool Reveals Key Lymphoma Genes
Traditionally, CRISPR-Cas9 has been the predominant system for gene editing, but limitations such as sequence constraints and off-target effects have driven the search for alternative tools.